Emcitate
What Emcitate is used for
Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Emcitate
- Active substance
- tiratricol
- Disease area
- Thyrotoxicosis; Heredodegenerative Disorders, Nervous System
- Medicine group
- Thyroid therapy
- ATC code
- H03AA04
- Marketing authorisation holder
- Rare Thyroid Therapeutics International AB
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Emcitate
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Emcitate used for?
Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.
What is the active substance in Emcitate?
Emcitate contains tiratricol.
Who makes Emcitate?
The EU marketing authorisation holder is Rare Thyroid Therapeutics International AB.
Is Emcitate an orphan medicine?
Yes. Emcitate is designated an orphan medicine in the EU, for a rare disease (Thyrotoxicosis; Heredodegenerative Disorders, Nervous System).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU